

6th

International Conference on

Thrombosis and Hemostasis Issues in Cancer

Seminario Vescovile
Beato "Giovanni XXIII"
Bergamo, Italy

April 20-22, 2012



Program



www.ictthic.com



A LEO Pharma sponsored satellite symposium

Cancer and Thrombosis; the quest for optimal care

Friday 20 April 2012, 09.30–12.30

Main Lecture Hall

Seminario Vescovile Beato 'Giovanni XXIII'

The symposium deals with the challenges and unresolved issues physicians face in attempting to provide optimal care to cancer patients with VTE.

Cancer and Thrombosis Survey

In collaboration with LEO Pharma, Professor Isabelle Mahé (Paris, France) is conducting a survey that aims to obtain a picture of your clinical practice in cancer and thrombosis, and the role that guideline recommendations play in your clinical decisions.

The questionnaire can be found in the congress bag or at the LEO Pharma stand.
Please hand in your completed questionnaire at the LEO Pharma stand.



6th International Conference on

Thrombosis and Hemostasis Issues in Cancer

Seminario Vescovile Beato "Giovanni XXIII"

Bergamo, Italy

April 20-22, 2012



Program



AUSPICES

The meeting will be held under the auspices of



PROVINCIA DI BERGAMO



COMUNE DI BERGAMO



Ospedali Riuniti di Bergamo



EUROPEAN
HEMATOLOGY
ASSOCIATION



GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE
European Society for Medical Oncology



Medical Women's
International
Association



www.fcsa.it

FEDERAZIONE
CENTRI PER LA DIAGNOSI
DELLA TROMBOSI E LA
SORVEGLIANZA DELLE TERAPIE
ANTITROMBOTICHE (FCSA)



Società Italiana per lo Studio
dell'Emostasi e della Trombosi



Associazione Italiana
di Oncologia Medica



SIMTI

Società Italiana di Medicina
Trasfusionale e Immunoematologia



Società
Italiana
di Ematologia

CONFERENCE ORGANIZATION

CONFERENCE CHAIRMEN

Anna Falanga

Division of Immunohematology and
Transfusion Medicine
& Hemostasis and Thrombosis Center
A.O. Ospedali Riuniti di Bergamo
Largo Barozzi, 1 - 24128 Bergamo, Italy
E-mail: annafalanga@yahoo.com

Benjamin Brenner

Department of Hematology
and Bone Marrow Transplantation
& Thrombosis and Hemostasis Unit
Rambam Health Care Campus
Technion, Israel Institute of Technology
POB 9602 Haifa, Israel
E-mail: b_brenner@rambam.health.gov.il

Frederick R. Rickles

The George Washington University
Katzen Cancer Center
2150 Pennsylvania Ave NW
Washington, DC 20037, USA
& Division of Hematology
Department of Medicine
Veterans Affairs Medical Center
50 Irving St NW
Washington, DC 20422, USA
E-mail: frederick.rickles@gmail.com

ORGANIZING COMMITTEE

Anna FALANGA
Bergamo, Italy

Frederick R. RICKLES
Washington, DC, USA

Benjamin BRENNER
Haifa, Israel

Laura CHIAPPA
Bergamo, Italy

Tiziano BARBUI
Bergamo, Italy

Roberto LABIANCA
Bergamo, Italy

Marina MARCHETTI
Bergamo, Italy

Alfonso VIGNOLI
Bergamo, Italy

Galit SARIG
Haifa, Israel

Elena GATTI
Bergamo, Italy

Laura RUSSO
Bergamo, Italy

Carmen Julia TARTARI
Bergamo, Italy

SCIENTIFIC SECRETARIAT

Anna Falanga Marina Marchetti Alfonso Vignoli

Division of Immunohematology and Transfusion Medicine & Hemostasis and Thrombosis Center
A.O. Ospedali Riuniti di Bergamo
Largo Barozzi, 1 - 24128 Bergamo, Italy
e-mail: scientificsecretariat@icthic.com

ORGANIZING SECRETARIAT

C.E.C. Srl

Servizi Congressuali ed Eventi Culturali

Via G. Verdi, 18 - 24121 Bergamo - Italy
Phone +39.035.249899 - Fax +39.035.237852 - E-mail: info@icthic.com



PROGRAM OVERVIEW

Friday April 20 th , 2012		Saturday April 21 st , 2012		Sunday April 22 nd , 2012	
08.00	Secretariat Opening	08.00	Secretariat Opening	08.00	Secretariat Opening
09.30	Satellite Symposia 09.30 - 12.30 Auditorium 11.30 - 13.00 Aula Magna Orlandi	08.15	Plenary Session 3 Bleeding complications in cancer patients Auditorium	08.15	Plenary Session 7 Platelets and vascular endothelium Auditorium
12.30	Special Session Advances in the management of complement disorders Room A	10.30		10.30	
13.00		10.30	Coffee Break	10.30	Coffee Break
13.30		11.00		11.00	
14.00	Congress Opening Auditorium	11.00	Plenary Session 4 Coagulation and cancer progression Auditorium	11.00	Plenary Session 8 Prevention and treatment of thrombosis Auditorium
14.15		13.15		13.15	
14.15	Plenary Session 1 Epidemiology and risk factors of venous thromboembolism Auditorium	13.15	Lunch Lunch Session Room B	13.15	Lunch
16.30		14.15		14.15	
16.30	Coffee Break	14.15	Plenary Session 5 Hematological disorders Auditorium	14.15	Poster Discussion Sessions Session 1: Room A Session 2: Room B Session 3: Room C Session 4: Room D
17.00		16.30		15.45	
17.00	Plenary Session 2 Genomics and proteomics of the hemostatic system in cancer Auditorium	16.30	Coffee Break	15.45	Coffee Break
19.15		17.00		16.15	
19.30	2nd Simon Karparkin Memorial Lecture Auditorium	17.00	Plenary Session 6 Anticoagulants and cancer Auditorium	16.15	Poster Discussion Sessions Session 5: Room A Session 6: Room B Session 7: Room C
20.30		19.15		17.30	
20.30	Welcome Reception	20.30	Presidential Dinner by invitation only	20.30	Farewell Party extra fee required

PROGRAM

Satellite Symposia & Lunch Session

Friday 20th, 2012

From 9.30 to 13.00: Auditorium and Room "Aula Magna Orlandi"

From 12.30 to 13.30: Room A

(for detailed programs see page 30)

Saturday 21st, 2012

From 13.15 -14.15: Room B

(for detailed program see page 30)

Special Session (Room A)

Friday 20th, 2012

ADVANCES IN THE MANAGEMENT OF COMPLEMENT DISORDERS

12.30 -13.30 Chairs: G. Remuzzi (Italy), S. Siragusa (Italy)

(for detailed program see page 19)

Friday April 20th, 2012

Congress Opening

14.00 - 14.15 Opening remarks from the Conference Chairmen, A. Falanga, F.R. Rickles, B. Brenner, and representatives of local authorities.

Scientific Sessions (Auditorium)

- 14.15 - 16.30 **Plenary Session 1**
EPIDEMIOLOGY AND RISK FACTORS OF VENOUS THROMBOEMBOLISM
Chairs: H.A. Liebman (USA), I. Pabinger (Austria)
- 14.15 - 14.40 **Predictive potential of hemostatic biomarkers** **PL-01**
I. Pabinger (Austria)
- 14.40 - 15.05 **Update on thrombotic risk stratification** **PL-02**
A. Khorana (USA)
- 15.05 - 15.30 **Unsuspected PE in cancer patients** **PL-03**
M. Monreal (Spain)
- 15.30 - 15.55 **Cancer in pregnancy** **PL-04**
B. Brenner (Israel)
- 15.55 - 16.10 **Selected Abstracts**
Rate of venous thromboembolism by cancer type compared to the general population using multiple linked databases **OC-01**
A.J. Walker, J. West, T.R. Card, C. Crooks, M.J. Grainge (UK)
- 16.10 - 16.25 **Thromboembolic complications in children with cancer: data from the italian registry of childhood thrombosis (RITI)** **OC-02**
M.C. Putti, C. Gentilomo, E. Cavaliere, P. Saracco, P. Giordano, A.C. Molinari, M. Grassi, V. Buccella, A. Falanga, D. Sperli, P. Simioni & Gruppo Italiano per il Registro Trombosi Infantile (GIRTI) (Italy)
- 16.30 - 17.00 **Coffee break**



PROGRAM

Friday April 20th, 2012 (cont'd)

17.00 - 19.15	Plenary Session 2 (Auditorium) GENOMICS AND PROTEOMICS OF THE HEMOSTATIC SYSTEM IN CANCER Chairs: F.R. Rickles (USA), M. Cattaneo (Italy)
17.00 - 17.25	Genetic pathways linking hemostasis and cancer PL-05 J. Rak (Canada)
17.25 - 17.50	Platelet CLEC-2 in lymphangiogenesis and cancer metastasis PL-06 S.P. Watson (UK)
17.50 - 18.15	Platelet systems biology and biomarker discovery PL-07 W.F. Bahou (USA)
18.15 - 18.40	Akt and Ras pathways and modulation of TF expression in glioblastoma PL-08 D. Brat (USA)
	Selected Abstracts
18.40 - 18.55	Trypsinogen IV, a new player in tumor angiogenesis OC-03 C. Ghilardi, S. Figini, M. Lupi, R. Fruscio, R. Giavazzi, M.R. Bani (Italy)
18.55 - 19.10	Novel functions of TFPI isoforms in breast cancer cells OC-04 B. Stavik, G. Skretting, M. Tinholt, M. Sletten, P. Sandset, N. Iversen (Norway)
19.30 - 20.30	Second Simon Karparkin Memorial Lecture (Auditorium) Introduction F.R. Rickles (USA) Hemostasis, innate immunity and malignancy J.L. Degen (USA)

Saturday April 21st, 2012

08.15 - 10.30	Plenary Session 3 (Auditorium) BLEEDING COMPLICATIONS IN CANCER PATIENTS Chairs: C.M. Kessler (USA), C. Velati (Italy)
08.15 - 08.40	Side effects of anti-angiogenic drugs PL-09 F. Rodeghiero (Italy)
08.40 - 09.05	Diagnosis and treatment of disseminated intravascular coagulation PL-10 C.-H. Toh (UK)
09.05 - 09.30	Transfusion issues in the cancer patient PL-11 A.B. Federici (Italy)
09.30 - 09.55	Acquired hemophilias in cancer PL-12 N.S. Key (USA)
	Selected Abstracts
09.55 - 10.10	Bleeding complications in patients with CKD and malignancy during anticoagulant treatment for venous thromboembolism OC-05 J. Kooiman, P.L. den Exter, A. Gedik, J. Hooijer, M.V. Huisman (The Netherlands)
10.10 - 10.25	Evaluation of platelet function and thromboxane A2 production in aspirin-treated patients with essential thrombocythemia OC-06 F. Lussana, E.A. Femia, M. Pugliano, G. Podda, C. Razzari, N. Maugeri, A. Lecchi, G. Motta, S. Caberlon, G. Gerli, M. Cattaneo (Italy)
10.30 - 11.00	Coffee break

Saturday April 21st, 2012 (cont'd)

11.00 - 13.15	Plenary Session 4 (Auditorium) COAGULATION AND CANCER PROGRESSION Chairs: M.B. Donati (Italy), R. Labianca (Italy)
11.00 - 11.25	The respective roles of TF isoforms in cancer PL-13 H.H. Versteeg (The Netherlands)
11.25 - 11.50	Heparanase procoagulant activity PL-14 Y. Nadir (Israel)
11.50 - 12.15	Protein C and cancer PL-15 C.A. Spek (The Netherlands)
12.15 - 12.40	Accounting for death as a competing risk in cancer VTE studies PL-16 J.I. Zwicker (USA)
	Selected Abstracts
12.40 - 12.55	Binding of anti-GRP78 autoantibodies to cell surface GRP78 promotes cancer progression by activating tissue factor procoagulant activity. OC-07 A.A. Al-Hashimi, F. Majeed, M. Gonzalez-Gronow, R.C. Austin (Canada, USA)
12.55 - 13.10	Studying cell-microenvironment interactions in a microfluidics model of tumor microcirculation. OC-08 Z.N. Demou, V. Turitto (USA)
13.15 - 14.15	Lunch
13.15 - 14.15	Lunch Session (Room B) (for detailed program see page 30)
14.15 - 16.30	Plenary Session 5 (Auditorium) HEMATOLOGICAL DISORDERS Chairs: G.H. Lyman (USA), R. Giavazzi (Italy)
14.15 - 14.40	Risk and management of thrombosis in multiple myeloma PL-17 F.W. Leebeek (The Netherlands)
14.40 - 15.05	The role of JAK-2 inhibition PL-18 A. Rambaldi (Italy)
15.05 - 15.30	Splanchnic vein thrombosis: New risk factors and management PL-19 W. Ageno (Italy)
15.30 - 15.55	CXCL-4 platelet factor 4, heparin-induced thrombocytopenia and cancer PL-20 P.M. Sandset (Norway)



PROGRAM

Saturday April 21st, 2012 (cont'd)

Selected Abstracts

15.55 - 16.10 **New potential markers of severe thrombo-hemorrhagic syndrome (THS) in acute promyelocytic leukemia (APL) patients: activated FVII-antithrombin complex (FVIIa-AT) and Tissue Factor (TF) mRNA** **OC-09**
M. Marchetti, L. Russo, C.J. Tartari, B. Woodhams, E. Di Bona, A. Rambaldi, F. Lo Coco, A. Falanga (Italy)

16.10 - 16.25 **The pathogenesis of warfarin-associated venous limb ischemia and gangrene complicating cancer: clinical and laboratory parallels with heparin-induced thrombocytopenia (HIT).** **OC-10**
T.E. Warkentin, R. Sarode, M.A. Johnston, M.A. Crowther (USA)

16.30 - 17.00 *Coffee break*

17.00 - 19.15 **Plenary Session 6** (Auditorium)
ANTICOAGULANTS AND CANCER
Chairs: S. Schulman (Canada), H.R. Büller (The Netherlands)

17.00 - 17.25 **New and old anticoagulants in cancer** **PL-21**
G. Agnelli (Italy)

17.25 - 17.50 **Guidelines for antithrombotics in cancer patients** **PL-22**
D. Farge-Bancel (France)

17.50 - 18.15 **Measurement of new oral anticoagulants** **PL-23**
J. Harenberg (Germany)

18.15 - 18.40 **LMWH and survival in lung cancer** **PL-24**
S. Noble (UK)

Selected Abstracts

18.40 - 18.55 **The effect of aspirin on cancer mortality** **OC-11**
T. Meade (UK)

18.55 - 19.10 **New antithrombotic agents in the treatment of VTE: a subgroup analysis of the Phase III randomized clinical trials** **OC-12**
G.T. Gerotziakas, M.M. Samama, I. Elalamy (France)

Sunday April 22nd, 2012

08.15 - 10.30 **Plenary Session 7** (Auditorium)
PLATELETS AND VASCULAR ENDOTHELIUM
Chairs: C.W. Francis (USA), H. ten Cate (The Netherlands)

08.15 - 08.40 **The role of thrombomodulin in tumor growth and metastasis** **PL-25**
N. Horowitz (Israel)

08.40 - 09.05 **Endothelial cell activation markers in cancer** **PL-26**
A.D. Blann (UK)

09.05 - 09.30 **Novel functions of tissue factor in thrombosis and in cancer** **PL-27**
W. Ruf (USA)

09.30 - 09.55 **Microparticles in tumor progression** **PL-28**
A. Falanga (Italy)

Sunday April 22nd, 2012 (cont'd)

Selected Abstracts

09.55 - 10.10 **On the use of anti-platelet drugs to diminish both tumor growth and thrombosis.** **OC-13**
R. Darbousset, S. Mezouar, R. Bonier, V. Sbarra, D. Farge-Bancel, C. Frère, C. Dubois, L. Panicot-Dubois (France)

10.10 - 10.25 **Cellular origin and procoagulant activity of tissue factor-exposing microparticles in cancer patients.** **OC-14**
A. Kleinjan, R.J. Berckmans, A.N. Böing, A. Sturk, H.R. Büller, P.W. Kamphuisen, R. Nieuwland (The Netherlands)

10.30 - 11.00 *Coffee break*

11.00 - 13.15 **Plenary Session 8** (Auditorium)
PREVENTION AND TREATMENT OF THROMBOSIS

Chairs: M.N. Levine (Canada), P. Prandoni (Italy)

11.00 - 11.25 **Thromboprophylaxis in the surgical cancer patient** **PL-29**
A.K. Kakkar (UK)

11.25 - 11.50 **Thromboprophylaxis in the non-surgical cancer patient** **PL-30**
A.T. Cohen (UK)

11.50 - 12.15 **Treatment of established thrombotic events** **PL-31**
A.Y. Lee (Canada)

12.15 - 12.40 **Overview of thrombosis and cancer survival** **PL-32**
N. Kuderer (USA)

Selected Abstracts

12.40 - 12.55 **Use of vena cava filters in cancer patients in California.** **OC-15**
R.H. White, A. Brunson, S. Murin, D.J. Tancredi, T. Wun (USA)

12.55 - 13.10 **Incidence of venous thromboembolism in patients undergoing laparoscopic surgery for colorectal cancer.** **OC-16**
M.C. Vedovati, C. Becattini, F. Rondelli, M. Boncompagni, G. Camporese, R. Balzarotti, E. Mariani, D. Flamini, G. Natalini, G. Agnelli (Italy)

13.15 - 14.30 *Lunch*

Poster Discussion Sessions

14.30 - 15.45 **Poster Discussion Sessions 1, 2, 3 and 4** (Rooms A, B, C and D, see pages 12-15)

15.45 - 16.15 *Coffee break*

16.15 - 17.30 **Poster Discussion Sessions 5, 6, and 7** (Rooms A, B, and C, see pages 16-18)

17.30 **Meeting closed**



POSTER DISCUSSION SESSIONS

Poster Session 1: EPIDEMIOLOGY

Room A

Chairs: A. Maraveyas (UK), B. Cosmi (Italy)

Sunday April 22nd, 2012
14.30 - 15.45

- PO-01 Long term clinical outcomes of cancer associated venous thromboembolism: findings from the MASTER registry**
D. Imberti, G. Agnelli, W. Ageno, M. Moia, G. Palareti, R. Pistelli, M. Verso, for the MASTER investigators. (Italy)
- PO-02 Rate and time course of thromboembolism events in cancer patients**
R. Hull, T. Merali, A. Mills, J. Liang, N. Komari. (Canada)
- PO-03 Are high D-Dimer levels in patients with acute VTE a sign of possible occult cancer?**
S. Cavazza, C. Legnani, C. Pili, G. Palareti. (Italy)
- PO-04 Venous thromboembolism: the interaction between prostate cancer and comorbidities and its impact on prognosis**
M. Nguyen-Nielsen, E. Horvath-Puho, A. Gulbech Ording, M. Vyberg, T.L. Lash, H.T. Sørensen. (Denmark, USA)
- PO-05 Does comorbidity interact with colon cancer to increase the risk of venous thromboembolism?**
R. Erichsen, E. Horváth-Puhó, A. Ording, M. Vyberg, T.L. Lash, H.T. Sørensen (Denmark, USA)
- PO-06 The value of thoraco-abdominal CT scanning for the detection of occult cancer in patients with unprovoked venous thromboembolism. A randomized study**
A. Piccioli, E. Bernardi, F. Dalla Valle, A. Visonà, P.F. Tropeano, C. Bova, E. Bucherini, P. Prandoni. (Italy)
- PO-07 Venous thromboembolism and haemostatic disturbances in patients with upper gastrointestinal cancer**
A.C. Larsen, T. Dabrowski, R.V. Fisker, S.R. Kristensen, B.K. Møller, O. Thorlacius-Ussing. (Denmark)
- PO-08 Prevalence of pulmonary embolism in colorectal cancer at time of diagnosis**
M. Poulsen, A.C. Larsen, R. Leusink, J.B. Frøkjær, T. Mandøe, M. Stender, O. Thorlacius-Ussing. (Denmark)
- PO-09 The role of 18-fluorine-fluorodeoxyglucose positron emission tomography in the evaluation of deep vein thrombosis**
M.T. Rondina, U.T. Lam, R.C. Pendleton, L.W. Kraiss, N. Wanner, G.A. Zimmerman, C. Hanrahan, K. Boucher, J.M. Hoffman, K.A. Morton. (USA)
- PO-10 Khorana risk score and PROTECHT risk score as prediction models of venous thromboembolism in cancer outpatients receiving chemotherapy: a retrospective analysis**
S. Barni, R. Labianca, M. Verso, G. Gasparini, E. Bonizzoni, M. Mandalà, M. Brighenti, F. Petrelli, C. Bianchini, T. Perrone, G. Agnelli. (Italy)
- PO-11 Esophageal variceal bleeding as a potential marker of liver cancer in patients with liver cirrhosis**
J. Montomoli, R. Erichsen, F. Mehnert, H.T. Sørensen. (Denmark)
- PO-12 Severity-of-illness in cancer patients contributes to the risk of hospital-acquired venous thromboembolism (VTE), but not post-discharge VTE**
S. Kaatz, R.H. White, D.J. Tancredi, T. Wun, J. Schein, L. Fields, C.V. Damaraju, M. Raut, B. Danielsen. (USA)
- PO-13 Breast cancer and comorbidity and risk of venous thromboembolism: a Danish nationwide population based cohort study**
A.G. Ording, E. Horváth-Puhó, M. Vyberg, H.T. Sørensen, T.L. Lash. (Denmark, USA)
- PO-14 Preoperative D-dimer levels predict long-term disease-free survival in patients with curatively intended resection for stage III colorectal cancer: a prospective cohort study**
K.G. Sunesen, M.T. Stender, O. Thorlacius-Ussing. (Denmark)
- PO-14^{bis} Prevalence of unexpected pulmonary embolism at CT scan for cancer staging in patients with lung cancer**
M. Verso, G. Agnelli, S. Mosca, M. Fischer, V. Marconi, R. Chiari, L. Crinò. (Italy)

Poster Session 2: **TISSUE FACTOR**

Room B

Chairs: R. Lorenzet (Italy), E. Faioni (Italy)

Sunday April 22nd, 2012
14.30 - 15.45

- PO-15 T cells, tissue factor and malignancy**
M.M. D'Elia, M. Benagiano, A. Amedei, C. Della Bella, E. Niccolai, D. Prisco. (Italy)
- PO-16 Cryogenic- and room- temperature electron microscopy imaging of MDA231 breast cancer cells and microparticles using immunogold labeling**
L. Issman, A. Aharon, B. Brenner, Y. Talmon. (Israel)
- PO-17 Alternatively spliced tissue factor triggers breast tumor growth**
B. Kocatürk, C. Tiekens, P.H. Reitsma, V.Y. Bogdanov, H.H. Versteeg. (The Netherlands, USA)
- PO-18 Induction of apoptosis and tissue factor (TF) expression in germ cell tumor cell lines by cisplatin chemotherapy**
C. Jacobsen, B. Spath, C. Bokemeyer, K. Dechsle, F. Honecker, F. Langer. (Germany)
- PO-19 Interplay of tissue factor splice variants in thrombosis**
C. Tiekens, Y.W. van den Berg, E.M. de Kruijff, P.J.K. Kuppen, P.H. Reitsma, V.Y. Bogdanov, H.H. Versteeg. (The Netherlands, USA)
- PO-20 Involvement of tissue factor expressed by cancer cells on tumor growth and thrombosis associated with cancer**
S. Mezouar, R. Darbousset, S. Germain, C. Frère, L. Panicot-Dubois, C. Dubois. (France)
- PO-21 Upregulation of tissue factor expression by avastin: ex vivo and in vitro data**
E. Napoleone, A. Cutrone, D. Cugino, R. Tambaro, A. De Curtis, L. Iacoviello, M.B. Donati, R. Lorenzet. (Italy)
- PO-22 Does tissue factor and tissue factor pathway inhibitor over expression, play a role in the development of venous thromboembolism in ovarian cancer patients?**
F. Abu Saadeh, L. Norris, S. O'Toole, R. Langhe, J.J. O'Leary, N. Gleeson. (Ireland)
- PO-23 The role of breast cancer cell microparticles in thrombogenicity and angiogenesis following chemotherapy**
A. Aharon, S. Nussbaum, G. Bar-Sela, D. Loven, B. Brenner. (Israel)
- PO-24 Peripheral blood microparticle-associated tissue factor activity in stage III and IV lung cancer**
F. Martino, T. Neri, I. Prediletto, L. Villari, M. Zurlo, S. Cini, A. Chella, E. Mariani, A. Palla, A. Celi, L.M. Tavanti. (Italy)
- PO-25 Human pancreatic cancer cell tissue factor activates coagulation in a mouse model**
J.G. Wang, J. Gambone, M.M. Aleman, J.C. Cardenas, P. Chantrathammachart, J.C. Williams, D. Kirchhofer, V.Y. Bogdanov, R.R. Bach, F.C. Church, A.S. Wolberg, R. Pawlinski, N.S. Key, J.J. Yeh, N. Mackman. (USA)
- PO-26 Circulating glial-derived and tissue factor bearing microparticles in patients with high grade glioma**
M.T. Sartori, A. Della Puppa, A. Ballin, E. Campello, C.M. Radu, G. Saggiorato, D. d'Avella, G. Cella, P. Simioni. (Italy)
- PO-27 Intercellular transfer of tissue factor upon the uptake of tumor-derived microvesicles**
L.G. Lima, A. Da Silva de Oliveira, R.Q. Monteiro. (Brazil)



POSTER DISCUSSION SESSIONS

Poster Session 3: HEMOSTATIC ALTERATIONS

Room C

Chairs: G. Sarig (Israel), A. Balduini (Italy)

Sunday April 22nd, 2012
14.30 - 15.45

- PD-28 Monocyte count associates with subsequent symptomatic venous thromboembolism (VTE) in hospitalized patients with solid tumors**
P. Rojnuckarin, N. Uaprasert, V. Sriuranpong. (Thailand)
- PD-29 The procoagulant response to cancer surgery is increased in early breast cancer with poor prognosis phenotypes**
H. Shaker, N.J. Bundred, C.C. Kirwan. (UK)
- PD-30 Platelets dysfunction in multiple myeloma**
I. Djunic, I. Elezovic, V. Ilic, D. Tomin, J. Bila, N. Suvajdzic-Vukovic, D. Antic, A. Vidovic, N. Milosevic-Jovcic. (Serbia)
- PD-31 Differential response of acute phase markers in lymphoid leukaemias - A probable diagnostic tool**
O.I. Ajayi, G. Nwaeke, Y.A. Djuade. (Nigeria)
- PD-32 Soluble endothelial protein C receptor (sEPCR) and coagulation parameters as prognostic factors in advanced non small cell lung cancer (NSCLC)**
G. Sarig, A. Meir, M. Wollner, I. Shafat, B. Brenner, N. Haim. (Israel)
- PD-33 Plasma vascular cell adhesion molecule 1, intercellular adhesion molecule 1 and osteoprotegerin levels in rectal cancer patients exposed to preoperative radiotherapy: a clinical prospective cohort study**
M.T. Stender, L.M. Rasmussen, T.B. Larsen, O. Thorlacius-Ussing. (Denmark)
- PD-34 Factor VIIa-antithrombin complexes plasma levels in cancer patients with and without thrombosis**
L. Spiezia, E. Campello, M. Bon, S. Gavasso, B. Woodhams, P. Simioni. (Italy, France)
- PD-35 Hemorrhagic diathesis in patient with multiple myeloma - case report**
L. Bartošová, I. Plamenová, P. Hollý, P. Kubisz. (Slovakia)
- PD-36 Elevated markers of hemostasis, fibrinolysis and angiogenesis in patients with advanced prostate cancer decrease following hormonal therapy in responding patients**
J.E. Arnason, N.H. Akhtar, M.Z. Afzal, A. Saran, D.M. Nanus, S.T. Tagawa. (USA)
- PD-37 Cancer-related differences in morpho-functional status of peripheral blood platelets**
I. Vasilenko, A. Matveeva, V. Metelin, O. Bichenkov, A. Balkanov. (Russia)
- PD-38 Structure of congenital and acquired thrombophilia in cancer patients with thrombotic complication in past history**
A.V. Vorobev, A.D. Makatsaria, A.G. Solopova. (Russia)

Poster Session 4: NEW EXPERIMENTAL AND CLINICAL APPROACHES

Room D

Chairs: M. Carpenedo (Italy), M. Mandalà (Italy)

Sunday April 22nd, 2012
14.30 - 15.45

- PO-39 Immunomodulatory effects of vitamin K-antagonist acenocoumarol** S. Schroecksnadel, M. Jenny, K. Kurz, H. Schennach, G. Weiss, D. Fuchs. (Austria)
- PO-40 Screening for occult malignancy with 18-F-FDG-PET/CT in patients with unprovoked venous thromboembolism**
A. Alfonso, M. Redondo, T. Rubio, B. Del Olmo, P. Rodríguez-Wilhelmi, S. Varea, M.J. García Velloso, J.A. Páramo, R. Lecumberri. (Spain)
- PO-41 Safety and efficacy of an educational program in reducing thrombotic and infective complications of peripherally inserted central catheters (PICCs) in haematological patients**
A. Malato, A. Luppino, R. Pipitone, M.G. Donà, F. Acquaviva, F. Fabbiano. (Italy)
- PO-42 Evaluation of the efficacy of use of fibrinogen in acquired coagulopathies**
J. Martinez Marcos, A.C. Ramalhinho, J. Ribeiro, P. Amantegui, O. Fonseca. (Portugal)
- PO-43 Orally administered unfractionated heparin reduces lung tumour incidence in a rat model**
L. Hiebert, T. Ping, Z. Ye, J. Xiang. (Canada)
- PO-44 Thrombophilia in oncology patients: hypercoagulability evaluation and assessment of anticoagulant prophylaxis**
V.A. Sukhanov, O.Y. Petrova, N.V. Vlasova, A.A. Shestakov. (Russia)
- PO-45 Argatroban for treatment of vein thrombosis complicating heparin-induced thrombocytopenia in haemodialyzed multiple myeloma: a case report**
M. Giorgi Pierfranceschi, S. Orlando, S. Chiesa, M. Barbera, E. Montini, F. Lombardi, P. Rossini, G. Bologna, S.A. Bacciu. (Italy)
- PO-46 Testing for and treating cancer associated thrombosis: choice of anticoagulant**
M.J. Johnson, L. Sheard, S. Noble, A. Maraveyas, H. Prout, I. Watt, D. Dowding. (UK)
- PO-47 Use of recombinant activated factor VII in the treatment of bleeding in chemotherapy induced thrombocytopenia**
P. Kubisz, P. Holly, L. Bartosova, I. Plamenova, J. Stasko, J. Sokol. (Slovakia)
- PO-48 In vitro antioxidant and antitumor evaluation of new sulfated antithrombotic small molecules**
M. Correia-da-Silva, E. Sousa, H. Cidade, K. Choosang, P. Pakkong, M.H. Vasconcelos, M.M.M. Pinto (Thailand, Portugal)
- PO-49 Effect of heparins on thrombin generation and proangiogenic properties of breast tumor cells**
E. Diani, M. Marchetti, A. Vignoli, A. Falanga. (Italy)
- PO-50 Role of anticoagulant heparan sulfate in tumor angiogenesis of the uterine carcinoma**
A. de Agostini, J.-C. Tille. (Switzerland)



POSTER DISCUSSION SESSIONS

Poster Session 5: PROPHYLAXIS AND TREATMENT OF THROMBOSIS

Room A

Chairs: D. Imberti (Italy), V. Pengo (Italy)

Sunday April 22nd, 2012
16.15 - 17.30

- PO-51 Asymptomatic venous thrombotic events in ambulatory cancer patients: impact on survival**
T. Gary, K. Belaj, K. Steidl, M. Pichler, F. Eisner, F. Hafner, H. Froehlich, H. Samonigg, E. Pilger, M. Brodmann. (Austria)
- PO-52 Thrombotic superior vena cava syndrome in cancer patients: data from a single center cohort of 340 consecutive patients**
D. Reig, C. Font, I. Victoria, J. Villalta, B. Farrús, J.C. Reverter, D. Tàssies, A. Tuca, P. Gascon. (Spain)
- PO-53 E-alerts for the prevention of venous thromboembolism in onco-hematological inpatients: pilot evaluation of reasons for physicians' refusal of pharmacological thromboprophylaxis**
C. Lazo, R. Lecumberri, S. Varea, A. Alfonso, A. Fernández del Carril, M. Marqués, A. García-Mouriz, J.A. Páramo. (Spain)
- PO-54 Variability of response of thromboprophylaxis with fixed dose of enoxaparin in patients with primary adenocarcinoma of the lung undergoing lobectomy**
C. Papageorgiou, E. Marret, P. Van Dreden, F. Bonnet, B. Woodhams, A.C. Spyropoulos, G.T. Gerotziafas, I. Elalamy. (France, USA)
- PO-55 A pulmonary severity index (PESI)-Based competency that underpins a modular outpatient nurse lead PE (pulmonary embolism) service for cancer patients**
J. Palmer, G. Bozas, G. Avery, A. Stephens, A. Maraveyas. (UK)
- PO-56 Venous thromboembolism in cancer patients**
S. Sawant, A.A. Dhir, A. Daddi, P.T.V. Nair. (India)
- PO-57 A worldwide survey to assess the current approach to the treatment of patients with cancer and venous thromboembolism**
A. Kleinjan, A. Aggerwal, A. van der Geer, P.W. Kamphuisen, F.R. Rickles, C. Faselis, H.R. Buller. (The Netherlands, USA)
- PO-58 Outcome and characteristics of cancer patients with unsuspected PE managed under a specialised care pathway protocol - updated results**
A. Maraveyas, J. Palmer, G. Avery, A. Stephens, M. Elliot, J. Hunter, S. Dean, G. Bozas. (UK)
- PO-59 Vitamin K antagonists versus LMWH in the treatment of venous thromboembolism in patients with malignancy: an observational survey in daily clinical practice**
P.L. den Exter, J. Hooijer, O.M. Dekkers, M.V. Huisman. (The Netherlands)
- PO-60 Outpatient management of pulmonary embolism in cancer patients: data on a prospective cohort with 138 consecutive patients**
C. Font, V. Pereira, D. Reig, I. Victoria, A. Tagliapietra, A. Tuca, P. Gascon. (Spain)
- PO-61 Use of low molecular-weight heparins in cancer patients with renal impairment: a review**
J-B. Rey, V. Launay-Vacher, F. Scotte. (France)
- PO-62 Risk of venous thromboembolism after hospitalisation with cancer: record linkage study**
S. Arjinian, D. Seminog, M.J. Goldacre. (UK)
- PO-63 Preoperative preparation in prophylaxis of thrombotic complications in cancer patients**
A.V. Vorobev, A.D. Makatsaria, A.G. Solopova. (Russia)
- PO-64 Primary VTE prophylaxis in ambulatory cancer patients receiving chemotherapy - a cost analysis**
A. Rossi, B. Schackman, N.H. Akhtar, S.T. Tagawa. (USA)
- PO-65 Variability of INR in a sample of cancer patients in the WARP trial**
A. Young, G. Begum, A. Ashton. (UK)
- PO-65bis International registry on the treatment of unsuspected pulmonary embolism in cancer patients**
M. Di Nisio, A. Kleinjan, P.W. Kamphuisen, J. Beyer, H-M Otten, H.R. Buller. (Italy, The Netherlands, Germany)

Poster Session 6: NEW ASSAYS

Room B

Chairs: E. Castoldi (The Netherlands), P. Simioni (Italy)

Sunday April 22nd, 2012
16.15 - 17.30

- PD-66 Standardized TGA measurement on the coagulation analyzer Ceveron® alpha TGA with the new optimized fluorogenic module**
B. R. Binder *in Memoriam*, V. Kaufmann, J. Mager, G. Unzeitig, L. Wagner. (Austria)
- PD-67 Evaluation of assay performance monitoring Rivaroxaban with TECHNOCHROM anti-Xa on different analyzers**
M. Leitner, V. Kaufmann, J. Mager, S. Geiter, A. Siegemund, L. Wagner. (Austria, Germany)
- PD-68 Evaluation of assay performance monitoring direct Thrombin Inhibitors with TECHNOCLOT DTI**
M. Leitner, M. Riha, V. Kaufmann, J. Mager, S. Geiter, L. Wagner. (Austria)
- PD-69 The effect of malignancy and chemotherapy on thrombin generation in cancer patients**
A.H.B. Rahman; R.H. Waghorn; D.M. Patterson; A. Denholm; S.P. Gunningham; M.J. Currie; C.M.A. Frampton; M.P. Smith; B.A. Robinson. (New Zealand)
- PD-70** withdrawn
- PD-71 In vivo cleavage of protein S is a major determinant in thrombin generation and correlates with platelet count in individuals with hematological malignancies**
H.J.M. Brinkman, I. Dienava-Verdoold, M.R. Marchetti, L.C.J. te Boome, L. Russo, A. Falanga, H.R. Koene, K. Mertens. (The Netherlands, Italy)
- PD-72 Functional activity of natural anticoagulants in children with acute lymphoblastic leukemia during treatment**
N.V. Lipay, V.V. Dmitriev, M.B. Borisenok, G.N. Mychkova. (Belarus)
- PD-73 Impact of lobectomy on hypercoagulable state in patients with primary adenocarcinoma of the lung**
C. Papageorgiou, P. Van Dreden, E. Marret, F. Bonnet, B. Woodhams, A.C. Spyropoulos, I. Elalamy, G.T. Gerotziafas. (France, USA)
- PD-74 Calibrated automated thrombogram for determination of ATIII function**
N.N. Kolyadko, V.V. Dmitriev, V.I. Prokhorova, L.A. Derzhavets. (Belarus)
- PD-75 Comparison of microparticle subsets and procoagulant properties in polycythemia vera and essential thrombocythemia**
M.C. Trappenburg, M.C. van Aalderen, M. van Schilfgaarde, P.J. Molenaar, H. ten Cate, A. Leyte, W.E. Terpstra. (The Netherlands)
- PD-76 Procoagulant activity in patients with gynaecological malignancies and the effect of neoadjuvant chemotherapy**
F. Abu Saadeh, L. Norris, S. O'Toole, R. Langhe, N. Gleeson. (Ireland)
- PD-77 Novel approaches in the detection of binding of cancer cell microparticles to activated platelets**
R.L. Bradford, P. Chantrathammachart, M. Mooberry, M. Mazepa, J.G. Wang, S.L. Glover, D.A. Gabriel, N. Mackman, N.S. Key. (USA)
- PD-78 Follow up of thrombin-generation after prostate cancer surgery**
M. Benyo, T. Flasko, Zs Molnar, A. Kerenyi, Z. Batta, J. Harsfalvi. (Hungary)



POSTER DISCUSSION SESSIONS

Poster Session 7: HEMOSTATIC SYSTEM AND CANCER PROGRESSION

Room C

Chairs: A. D'Angelo (Italy), E. De Candia (Italy)

Sunday April 22nd, 2012
16.15 - 17.30

- PD-79** **Protease-activated receptor-2 (PAR2) mediates VEGF production through the ERK1/2 pathway in human glioblastoma cell lines**
A. Dutra-Oliveira, R.Q. Monteiro, A. Mariano-Oliveira. (Brazil)
- PD-80** **PAR-2 activation induces migration but not proliferation of pancreatic cancer cells**
K. Shi, K.C.S. Queiroz, C.A. Spek. (The Netherlands)
- PD-81** **Thrombin induces pancreatic cancer cell survival during growth factor deprivation**
K.C.S. Queiroz, T. Liechtenstein, C.A. Spek. (The Netherlands)
- PD-82** **Hypoxia induces Smad2 phosphorylation signaling and increases stem cell-like properties and multi-drug resistance in K562 leukemic cells**
X.-Y. Cui, G. Skretting, Y. Jing, C. F. Myklebust, Y.-F. Liu, P. M. Sandset, L. Sun. (Norway, China)
- PD-83** **Evidence that protease-activated receptor-2 (PAR-2) supports angiogenesis in a murine melanoma model**
A. Oliveira, A. Mariano, G. Montagner, R. Monteiro. (Brazil)
- PD-84** **Fibrinogen-like protein 2 (FGL-2) - a novel biomarker for cancer**
E. Rabizadeh, D. Lederfine, E. Rosenbaum, B. Brenner, A. Inbal. (Israel)
- PD-85** **Apoptosis in CHO-K1 cells overexpressing TFPI involves both intrinsic and extrinsic pathways additional to induced activation of NF- κ B**
G. Skretting, N. Iversen, C.F. Myklebust, A.E. Dahm, P.M. Sandset. (Norway)
- PD-86** **Cancer cells modify the microenvironment: R655 a novel endothelial protein of the abnormal tumor vasculature**
S. Figini, A. Sillini, C. Ghilardi, R. Fruscio, R. Giavazzi, M.R. Bani. (Italy)
- PD-87** **Inhibition of FGF-2 angiogenic activity by novel small molecules mimetic of thrombospondin-1 (TSP-1)**
C. Foglieni, R. Torella, A. Bugatti, K. Pagano, L. Ragona, D. Ribatti, M. Rusnati, M. Presta, R. Giavazzi, G. Colombo, G. Taraboletti. (Italy)
- PD-88** **Role of the FGF-2-binding fragment of thrombospondin-1 (TSP-1) in tumor progression**
A. Resovi, P. Borsotti, S. Bonifacio, P. Oliva, V. Castiglioni, R. Giavazzi, G. Taraboletti. (Italy)

SPECIAL SESSION

Friday April 20th, 2012

Special Session (Room A)

12.30 - 13.30 ADVANCES IN THE MANAGEMENT OF COMPLEMENT DISORDERS

Chairs: G. Remuzzi (Italy), S. Siragusa (Italy)

Thrombosis in paroxysmal nocturnal hemoglobinuria

I.C. Weitz (USA)

Hemolytic uremic syndrome and thrombosis

M. Noris (Italy)

www.icthic.com





AUTHOR INDEX

A

Abu Saadeh, F. PO-22, PO-76
 Acquaviva, F. PO-41
 Afzal, M.Z. PO-36
 Ageno, W. PL-19, PO-01
 Aggerwal, A. PO-57
 Agnelli, G. PL-21, OC-16, PO-01,
 PO-10, PO-14bis
 Aharon, A. PO-16, PO-23
 Ajayi, O.I. PO-31
 Akhtar, N.H. PO-36, PO-64
 Al-Hashimi, A.A. OC-07
 Aleman, M.M. PO-25
 Alfonso, A. PO-40, PO-53
 Amantegui, P. PO-42
 Amedei, A. PO-15
 Antic, D. PO-30
 Arjinián, S. PO-62
 Arnason, J.E. PO-36
 Ashton, A. PO-65
 Austin, R.C. OC-07
 Avery, G. PO-55, PO-58
 Ay, C. PL-01

B

Bacciu, S.A. PO-45
 Bach, R.R. PO-25
 Bahou, W.F. PL-07
 Balkanov, A. PO-37
 Ballin, A. PO-26
 Balzarotti, R. OC-16
 Bani, M.R. OC-03, PO-86
 Bar-Sela, G. PO-23
 Barbera, M. PO-45
 Barni, S. PO-10
 Bartošová, L. PO-35, PO-47
 Batta, Z. PO-78
 Becattini, C. OC-16
 Begum, G. PO-65
 Belaj, K. PO-51
 Benagiano, M. PO-15
 Benyo, M. PO-78
 Berckmans, R.J. OC-14
 Bernardi, E. PO-06
 Beyer, J. PO-65bis
 Bianchini, C. PO-10
 Bichenkov, D. PO-37

Bila, J. PO-30
 Binder, B.R. PO-66
 Blann, A.D. PL-26
 Bogdanov, V.Y. PO-17, PO-19, PO-25
 Böing, A.N. OC-14
 Bokemeyer, C. PO-18
 Bologna, G. PO-45
 Bon, M. PO-34
 Boncompagni, M. OC-16
 Bonier, R. OC-13
 Bonifacio, S. PO-88
 Bonizzoni, E. PO-10
 Bonnet, F. PO-54, PO-73
 Borisenok, M.B. PO-72
 Borsotti, P. PO-88
 Boucher, K. PO-09
 Bova, C. PO-06
 Bozas, G. PO-55, PO-58
 Bradford, R.L. PO-77
 Brat, D.J. PL-08
 Brenner, B. PL-04, PO-16, PO-23,
 PO-32, PO-84
 Brighenti, M. PO-10
 Brinkman, H.J.M. PO-71
 Brodmann, M. PO-51
 Brunson, A. OC-15
 Buccella, V. OC-02
 Bucherini, E. PO-06
 Bugatti, A. PO-87
 Büller, H.R. OC-14, PO-57, PO-65bis
 Bundred, N.J. PO-29

C

Caberlon, S. OC-06
 Campello, E. PO-26, PO-34
 Camporese, G. OC-16
 Card, T.R. OC-01
 Cardenas, J.C. PO-25
 Castiglioni, V. PO-88
 Cattaneo, M. OC-06
 Cavaliere, E. OC-02
 Cavazza, S. PO-03
 Celi, A. PO-24
 Cella, G. PO-26
 Chantrathammachart, P. PO-25, PO-77
 Chella, A. PO-24
 Chiari, R. PO-14bis
 Chiesa, S. PO-45

Choosang, K. PO-48
 Church, F.C. PO-25
 Cidade, H. PO-48
 Cini, S. PO-24
 Cohen, A.T. PL-30
 Colombo, G. PO-87
 Correia-da-Silva, M. PO-48
 Crinò, L. PO-14bis
 Crooks, C. OC-01
 Crowther, M.A. OC-10
 Cugino, D. PO-21
 Cui, X.-Y. PO-82
 Currie, M.J. PO-69
 Cutrone, A. PO-21

D

D'Avella, D. PO-26
 D'Elios, M.M. PO-15
 Da Silva de Oliveira, A. PO-27
 Dabrowski, T. PO-07
 Daddi, A. PO-56
 Dahm, A.E. PO-85
 DallaValle, F. PO-06
 Damaraju, C.V. PO-12
 Danielsen, B. PO-12
 Darbousset, R. OC-13, PO-20
 de Agostini, A. PO-50
 De Curtis, A. PO-21
 de Kruijf, E.M. PO-19
 Dean, S. PO-58
 Degen, J.L. 51
 (Simon Karparkin Memorial Lecture)
 Dekkers, D.M. PO-59
 Del Olmo, B. PO-40
 Della Bella, C. PO-15
 Della Puppa, A. PO-26
 Demou, Z.N. OC-08
 den Exter, P.L. OC-05, PO-59
 Denholm, A. PO-69
 Derzhavets, L.A. PO-74
 Dhir, A.A. PO-56
 Di Bona, E. OC-09
 Di Nisio, M. PO-65bis
 Diani, E. PO-49
 Dienava-Verdoold, J. PO-71
 Djunic, I. PO-30
 Dmitriev, V.V. PO-72, PO-74
 Donà, M.G. PO-41

Donati, M.B. PO-21
Dowding, D. PO-46
Dubois, C. OC-13, PO-20
Dutra-Oliveira, A. PO-79

E

Eisner, F. PO-51
Elalamy, I. OC-12, PO-54, PO-73
Elezovic, I. PO-30
Elliot, M. PO-58
Erichsen, R. PO-05, PO-11

F

Fabbiano, F. PO-41
Falanga, A. PL-28, OC-02, OC-09,
PO-49, PO-71
Farge-Bancel, PL-22, OC-13
Farrús, B. PO-52
Faselis, C. PO-57
Federici, A.B. PL-11
Femia, E.A. OC-06
Fernández del Carril, A. PO-53
Fields, L. PO-12
Figini, S. OC-03, PO-86
Fischer, M. PO-14bis
Fisker, R.V. PO-07
Flamini, D. OC-16
Flasko, T. PO-78
Foglieni, C. PO-87
Fonseca, D. PO-42
Font, C. PO-52, PO-60
Frampton, C.M.A. PO-69
Frère, C. OC-13, PO-20
Froehlich, H. PO-51
Frøkjær, J.B. PO-08
Fruscio, R. OC-03, PO-86
Fuchs, D. PO-39

G

Gabriel, D.A. PO-77
Gambone, J. PO-25
García Velloso, M.J. PO-40
García-Mouriz, A. PO-53
Gary, T. PO-51
Gascon, P. PO-52, PO-60
Gasparini, G. PO-10
Gavasso, S. PO-34
Gedik, A. OC-05

Geiter, S. PO-67, PO-68
Gentilomo, C. OC-02
Gerli, G. OC-06
Germain, S. PO-20
Gerotziakas, G.T. OC-12, PO-54, PO-73
Ghilardi, C. OC-03, PO-86
Giavazzi, R. OC-03, PO-86,
PO-87, PO-88
Giordano, P. OC-02
Giorgi Pierfranceschi, M. PO-45
Gleeson, N. PO-22, PO-76
Glover, S.L. PO-77
Goldacre, M.J. PO-62
Gonzalez-Gronow, M. OC-07
Grainge, M.J. OC-01
Grassi, M. OC-02
Gunningham, S.P. PO-69

H

Hafner, F. PO-51
Haim, N. PO-32
Hanrahan, C. PO-09
Harenberg, J. PL-23
Harsfalvi, J. PO-78
Hiebert, L. PO-43
Hoffman, J.M. PO-09
Hollg, P. PO-35, PO-47
Honecker, F. PO-18
Hooijer, J. OC-05, PO-59
Horowitz, N.A. PL-25
Horváth-Puhó, E. PO-04, PO-05, PO-13
Huisman, M.V. OC-05, PO-59
Hull, R. PO-02
Hunter, J. PO-58

I

Iacoviello, L. PO-21
Ilic, V. PO-30
Imberti, D. PO-01
Inbal, A. PO-84
Issman, L. PO-16
Iversen, N. OC-04, PO-85

J

Jacobsen, C. PO-18
Jenny, M. PO-39
Jing, Y. PO-82
Johnson, M.J. PO-46
Johnston, M.A. OC-10

K

Kaatz, S. PO-12
Kakkar, A.K. PL-29
Kamphuisen, P.W. OC-14, PO-57,
PO-65bis
Kaufmann, V. PO-66, PO-67, PO-68
Kerenyi, A. PO-78
Key, N.S. PL-12, PO-25, PO-77
Khorana, A.A. PL-02
Kirchhofer, D. PO-25
Kirwan, C.C. PO-29
Kleinjan, A. OC-14, PO-57, PO-65bis
Kocatürk, B. PO-17
Koene, H.R. PO-71
Kolyadko, N.N. PO-74
Komari, N. PO-02
Kooiman, J. OC-05
Kraiss, L.W. PO-09
Kristensen, S.R. PO-07
Kubisz, P. PO-35, PO-47
Kuderer, N. PL-32
Kuppen, P.J.K. PO-19, PO-39

L

Labianca, R. PO-10
Lam, U.T. PO-09
Langer, F. PO-18
Langhe, R. PO-22, PO-76
Larsen, A.C. PO-07, PO-08
Larsen, T.B. PO-33
Lash, T.L. PO-04, PO-05, PO-13
Launay-Vacher, V. PO-61
Lazo, C. PO-53
Lecchi, A. OC-06
Lecumberri, R. PO-40, PO-53,
PO-84
Lederfine, D. PO-84
Lee, A.Y.Y. PL-31
Leebeek, F.W.G. PL-17
Legnani, C. PO-03
Leitner, M. PO-67, PO-68
Leusink, R. PO-08
Leyte, A. PO-75
Liang, J. PO-02
Liechtenstein, T. PO-81
Lima, L.G. PO-27
Lipay, N.V. PO-72
Liu, Y.-F. PO-82



AUTHOR INDEX

Lo Coco, F. OC-09
Lombardi, F. PO-45
Lorenzet, R. PO-21
Loven, D. PO-23
Lupi, M. OC-03
Luppino, A. PO-41
Lussana, F. OC-06

M

Mackman, N. PO-25, PO-77
Mager, J. PO-66, PO-67, PO-68
Majeed, F. OC-07
Makatsaria, A.D. PO-38, PO-63
Malato, A. PO-41
Mandalà, M. PO-10
Mandøe, T. PO-08
Maraveyas, A. PO-46, PO-55, PO-58
Marchetti, M. OC-09, PO-49, PO-71
Marconi, V. PO-14bis
Mariancini, E. PO-24
Mariani, E. OC-16
Mariano, A. PO-83
Mariano-Oliveira, A. PO-79
Marqués, M. PO-53
Marret, E. PO-54, PO-73
Martinez Marcos, J. PO-42
Martino, F. PO-24
Matveeva, A. PO-37
Maugeri, N. OC-06
Mazepa, M. PO-77
Meade, T. OC-11
Mehnert, F. PO-11
Meir, A. PO-32
Merali, T. PO-02
Mertens, K. PO-71
Metelin, V. PO-37
Mezouar, S. OC-13, PO-20
Mills, A. PO-02
Milosevic-Jovicic, N. PO-30
Moia, M. PO-01
Molenaar, P.J. PO-75
Molinari, A.C. OC-02
Møller, B.K. PO-07
Molnar, Zs. PO-78
Montréal, M. PL-03
Montagner, G. PO-83
Monteiro, R.Q. PO-27, PO-79, PO-83

Montini, E. PO-45
Montomoli, J. PO-11
Mooberry, M. PO-77
Morton, K.A. PO-09
Mosca, S. PO-14bis
Motta, G. OC-06
Murin, S. OC-15
Mychkova, G.N. PO-72
Myklebust, C.F. PO-82, PO-85

N

Nadir, Y. PL-14
Nair, P.T.V. PO-56
Nanus, D.M. PO-36
Napoleone, E. PO-21
Natalini, G. OC-16
Neri, T. PO-24
Nguyen-Nielsen, M. PO-04
Nicolai, E. PO-15
Nieuwland, R. OC-14
Noble, S. PL-24, PO-46
Norris, L. PO-22, PO-76
Nussbaum, S. PO-23
Nwaeke, G. PO-31

O

O'Leary, J.J. PO-22
O'Toole, S. PO-22, PO-76
Oechsle, K. PO-18
Ojuade, Y.A. PO-31
Oliva, P. PO-88
Oliveira, A. PO-83
Ording, A.G. PO-04, PO-05, PO-13
Orlando, S. PO-45
Otten, H.-M. PO-65bis

P

Pagano, K. PO-87
Pakkong, P. PO-48
Palareti, G. PO-01, PO-03
Palla, A. PO-24
Palmer, J. PO-55, PO-58
Panicot-Dubois, L. OC-13, PO-20
Papageorgiou, C. PO-54, PO-73
Páramo, J.A. PO-40, PO-53
Patterson, D.M. PO-69
Pawlinski, R. PO-25
Pendleton, R.C. PO-09

Pereira, V. PO-60
Perrone, T. PO-10
Petrelli, F. PO-10
Petrova, O.Y. PO-44
Piccioli, A. PO-06
Pichler, M. PO-51
Pilger, E. PO-51
Pili, C. PO-03
Ping, T. PO-43
Pinto, M.M.M. PO-48
Pipitone, R. PO-41
Pistelli, R. PO-01
Plameňová, I. PO-35, PO-47
Podda, G. OC-06
Poulsen, M. PO-08
Prandoni, P. PO-06
Prediletto, I. PO-24
Presta, M. PO-87
Prisco, D. PO-15
Prokhorova, V.I. PO-74
Prout, H. PO-46
Pugliano, M. OC-06
Putti, M.C. OC-02

Q

Queiroz, K.C.S. PO-80, PO-81

R

Rabizadeh, E. PO-84
Radu, C.M. PO-26
Ragona, L. PO-87
Rahman, A.H.B. PO-69
Rak, J. PL-05
Ramalhinho, A.C. PO-42
Rambaldi, A. PL-18, OC-09
Rasmussen, L.M. PO-33
Raut, M. PO-12
Razzari, C. OC-06
Redondo, M. PO-40
Reig, O. PO-52, PO-60
Reitsma, P.H. PO-17, PO-19
Resovi, A. PO-88
Reverter, J.C. PO-52
Rey, J.-B. PO-61
Ribatti, D. PO-87
Ribeiro, J. PO-42
Rickles, F.R. PO-57
Riha, M. PO-68

Robinson,B.A.	PO-69
Rodeghiero,F.	PL-09
Rodríguez-Wilhelmi,P.	PO-40
Rojnuckarin,P.	PO-28
Rondelli,F.	OC-16
Rondina,M.T.	PO-09
Rosenbaum,E.	PO-84
Rossi,A.	PO-64
Rossini,P.	PO-45
Rubio,T.	PO-40
Ruf,W.	PL-27
Rusnati,M.	PO-87
Russo,L.	OC-09, PO-71

S

Saggiorato,G.	PO-26
Samama,M.M.	OC-12
Samonigg,H.	PO-51
Sandset,P.M.	PL-20, OC-04, PO-82, PO-85
Saracco,P.	OC-02
Saran,A.	PO-36
Sarig,G.	PO-32
Sarode,R.	OC-10
Sartori,M.T.	PO-26
Sawant,S.	PO-56
Sbarra,V.	OC-13
Schackman,B.	PO-64
Schein,J.	PO-12
Schennach,H.	PO-39
Schroecksnadel,S.	PO-39
Scotte,F.	PO-61
Seminog,D.	PO-62
Shafat,I.	PO-32
Shaker,H.	PO-29
Sheard,L.	PO-46
Shestakov,A.A.	PO-44
Shi,K.	PO-80
Siegemund,A.	PO-67
Silini,A.	PO-86
Simioni,P.	OC-02, PO-26, PO-34
Skretting,G.	OC-04, PO-82, PO-85
Sletten,M.	OC-04
Smith,M.P.	PO-69
Sokol,J.	PO-47
Solopova,A.G.	PO-38, PO-63
Sørensen,H.T.	PO-04, PO-05, PO-13
Sousa,E.	PO-48

Spath,B.	PO-18
Spek,C.A.	PL-15, PO-80, PO-81
Sperli,D.	OC-02
Spiezia,L.	PO-34
Spyropoulos,A.C.	PO-54, PO-73
Sriuranpong,V.	PO-28
Stasko,J.	PO-47
Stavik,B.	OC-04
Steidl,K.	PO-51
Stender,M.T.	PO-08, PO-14, PO-33
Stephens,A.	PO-55, PO-58
Sturk,A.	OC-14
Sukhanov,V.A.	PO-44
Sun,L.	PO-82
Sunesen,K.G.	PO-14
Suvajdzic-Vukovic,N.	PO-30

T

Tagawa,S.T.	PO-36, PO-64
Tagliapietra,A.	PO-60
Talmon,Y.	PO-16
Tambaro,R.	PO-21
Tancredi,D.J.	OC-15, PO-12
Taraboletti,G.	PO-87, PO-88
Tartari,C.J.	OC-09
Tàssies,D.	PO-52
Tavanti,L.M.	PO-24
Te Boome,L.C.J.	PO-71
ten Cate,H.	PO-75
Terpstra,W.E.	PO-75
Thorlacius-Ussing,O.	PO-07, PO-08, PO-14, PO-33
Tieken,C.	PO-17, PO-19
Tille,J.-C.	PO-50
Tinholt,M.	OC-04
Toft Sørensen,H.	PO-11
Toh,C.H.	PL-10
Tomin,D.	PO-30
Torella,R.	PO-87
Trappenburg,M.C.	PO-75
Tropeano,P.F.	PO-06
Tuca,A.	PO-52, PO-60
Turitto,V.	OC-08

U

Uaprasert,N.	PO-28
Unzeitig,G.	PO-66

V

van Aalderen,M.C.	PO-75
van den Berg,Y.W.	PO-19
van der Geer,A.	PO-57
Van Dreden,P.	PO-54, PO-73
van Schilfgaarde,M.	PO-75
Varea,S.	PO-40, PO-53
Vasconcelos,M.H.	PO-48
Vasilenko,I.	PO-37
Vedovati,M.C.	OC-16
Verso,M.	PO-01, PO-10, PO-14bis
Versteeg,H.H.	PL-13, PO-17, PO-19
Victoria,I.	PO-52, PO-60
Vidovic,A.	PO-30
Vignoli,A.	PO-49
Villalta,J.	PO-52
Villari,L.	PO-24
Visonà,A.	PO-06
Vlasova,N.V.	PO-44
Vorobev,A.V.	PO-38, PO-63
Vyberg,M.	PO-04, PO-05, PO-13

W

Waghorn,R.H.	PO-69
Wagner,L.	PO-66, PO-67, PO-68
Walker,A.J.	OC-01
Wang,J.G.	PO-25, PO-77
Wanner,N.	PO-09
Warkentin,T.E.	OC-10
Watson,S.P.	PL-06
Watt,I.	PO-46
Weiss,G.	PO-39
West,J.	OC-01
White,R.H.	OC-15, PO-12
Williams,J.C.	PO-25
Wolberg,A.S.	PO-25
Wollner,M.	PO-32
Woodhams,B.	OC-09, PO-34, PO-54, PO-73
Wun,T.	OC-15, PO-12

X

Xiang,J.	PO-43
----------	-------

Y

Ye,Z.	PO-43
Yeh,J.J.	PO-25
Young,A.	PO-65

Z

Zimmerman,G.A.	PO-09
Zurlo,M.	PO-24
Zwicker,J.I.	PL-16



GENERAL INFORMATION

Meeting venue

The Conference takes place in Bergamo at the
Seminario Vescovile Beato "Giovanni XXIII"
Via Arena, 11 - Bergamo, Città Alta (Uptown)

Organizing Secretariat

Servizi C.E.C. Srl

Servizi Congressuali ed Eventi Culturali
Via Verdi 18 - 24121 Bergamo - Italy
On site phone +39.035 286307
e-mail: info@icthic.com

Registration desk

The registration desk is located in the entrance hall of the Seminario Vescovile.

It is staffed continuously every day of the conference.
The staff is at your disposal for any information. Facilities available at the registration desk include:

On-site registration

Fees for on-site registration are:

- Full (Regular): Euro 520
- Student: Euro 100
- Accompanying person: Euro 130

Message boards

Any late change in the program of the conference or personal messages will be notified here.

Telephone and fax

Available on request.

Computing, printing and xeroxing

Available on request.

Internet Point

It is located at the ground floor, close to the registration desk.

Continuing Medical Education

The 6th International Conference on Thrombosis and Hemostasis Issues in Cancer has been granted for CME accreditation by:

◆ European Hematology Association (EHA)

18.5 CME points

for European Hematologists

The program of the 6th ICTHIC has been reviewed and approved for CME accreditation by the European Hematology Association CME Unit.

The EHA-CME Unit has approved this educational activity for a maximum number of 18.5 CME credits.

Each physician should only claim credits for time that she/he actually spent in the educational activity.

◆ European Society for Medical Oncology (ESMO)

20 ESMO-MORA category 1 points

for European Medical Oncologists

◆ Italy Ministry of Health (E.C.M.)

for Italian delegates

18 points for Medical Doctors (Hematology, Oncology, Transfusion Medicine, Clinical Biochemistry, Internal Medicine, Clinical Pathology)

18 points for Biologists

The instructions and the forms for claiming CME Credits are in the Congress bag.

Badges

All congress participants are kindly requested to wear the badge throughout the conference. Only badge holders will be admitted to the Scientific Sessions, Technical Exhibition, Welcome Reception, Coffee breaks and Lunches. For the Social Events please bring with you the ticket(s) delivered at registration.

Name badges are colored as follows:

Faculty	Red
Delegate	Blue
Accompanying person	Green

Certificates of Attendance

The certificates will be delivered at the registration desk starting from 13.00 on Sunday April 22nd.

Posters

Mounting time

Posters have to be mounted in the **Poster Area** from 09.00 Friday April 20th and during meeting opening hours.

Viewing Time

In the Poster Area from mounting to 11.00 Sunday April 22nd.

Mandatory attendance

During the discussion (see below).

Discussion

There will be 7 Poster Sessions each guided by two co-chairs (duration= 1h 15min), all held on Sunday April 22nd in **Rooms A-B-C-D**. Sessions 1, 2, 3 and 4 will be from 14.30 to 15.45; sessions 5, 6 and 7 will be from 16.15 to 17.30. Posters will be moved from the Poster Area to the respective room for discussion by the congress organization at the end of viewing time.

Presenting authors are required to attend during the entire discussion session.

Some posters have been chosen by the session chairs to be briefly orally presented as a start for discussion: the respective authors have been individually advised to prepare a few Powerpoint slides in addition to the printed poster. These presentations must be uploaded directly in the room during or just before the start of the respective poster session: they have NOT to be submitted to the congress Slide Center.

Dismantling

From 17.30 to 18.00 Sunday April 22nd. After this time all remaining posters will be destroyed by the organizing staff.

Dimensions

Maximum size of the Poster is **70 cm wide x 100 cm high** (vertical orientation). Material for poster mounting is available on site.

Slide Center

Slide center is located at the ground floor in front of the registration desk. All presenters should check in their slides or diskette/CD-ROM containing a PowerPoint presentation no later than 2 hours prior to the start of their session.

Language

The official language of the Conference is English. Translations are not provided.

Meals

Coffee/tea breaks and lunches are included in the Conference fee and are served in the catering areas located downstairs.

Cloakroom


Coats and bags may be left in the designated area.

Technical exhibition

The technical exhibition is located in the foyer at the ground floor. The exhibition opening times are the same of the Conference.



MEETING VENUE




Ground Floor

- 1** Slide Center
- 2** Registration Desk
- 3** Exhibition area
- 4** Auditorium
- 5** Room Aula Magna Orlandi
- 6** Internet point
- 7** Cloakroom

Basement

- 1** Room A
- 2** Room B
- 3** Room C
- 4** Room D
Catering area
Poster area
- 5** Catering area



SOCIAL PROGRAM

Social Events

Friday April 20th - 20.30

Welcome Reception

Included in the Registration fee. This event will take place at Seminario Vescovile Beato "Giovanni XXIII", the meeting venue.

Saturday April 21st - 20.30

Presidential Dinner

By invitation only.

Sunday April 22nd - 20.30

Farewell Party

Meeting point: Colle Aperto at 19.45

A reservation fee of € 50,00 (VAT included) must be paid in advance. This event will take place at Restaurant "San Vigilio" - Città Alta (Uptown)

Excursions

(for registered accompanying persons only, included in the registration fee)

Friday April 20th, 17.00 - 19.30

Visit to the new Historical Museum of the Venetian Age and to the City Tower (The Campanone)

Meeting point: Seminario Vescovile Beato "Giovanni XXIII" at 16.45

Historical Museum of the Venetian Age • The interactive 16th century, located in Palazzo del Podestà. In the Museum halls, new life is breathed into the history of Venetian Bergamo in multimedia storytelling, combining knowledge and games, intellect and emotions. Tokens from the past - paintings, manuscripts, maps and documents - come to life thanks to new technologies. **Palazzo del Podestà** has a long-lasting history. Built near the Palazzo della Ragione - home to civil power - and of the Vescovado - home to religious power - the palace with the **Torre del Campanone** looks onto the two squares that represented the centre of Bergamo in the municipal period (Piazza Duomo) and the Renaissance period (Piazza Vecchia). It was most probably built at the end of the twelfth century by the Suardi family, who donated it to the town. It was then used as the residence of the Podestà, the foreign governor in charge of managing the municipality for a six-month period, who could count on the prisons located underneath the tower, if necessary. When Bergamo became Terra di San Marco in 1428, the Palace was transformed in to the Law Courts and residence of the Vicario del Podestà.

Torre del Campanone It is in the shadows of the Civic Tower (the Campanone) that, for almost a thousand years, Bergamo experiences its most important moments: tales of

celebration, like when its bells call the faithful to celebrate the patron saint of Bergamo or announce the visit of emperors, podestàs or of the General Giuseppe Garibaldi; but also tragic tales, like the night of January 7, 1388 when the wind did great damage above the roofings of the Township of Bergamo; or, again, in March of 1797, when it is the tolls of the Civic Tower that invite citizens to celebrate the end of the Venetian rule and the raising of the liberty tree; daily tales, or when the peremptory and repeated nightly tolls of the bells remind the citizens that the entrance doors to the city are about to be closed (to this day, every night at 10 p.m. about a hundred tolls are a reminder of that time).

Saturday April 21st, 9.30 - 18.00

Milan - Cultural Sightseeing Tour in Milan and Brera Art Design District

Meeting point: Seminario Vescovile Beato "Giovanni XXIII" at 9.15

The bus will leave at 9.30 from the Seminario Vescovile Beato "Giovanni XXIII" for a visit of the most beautiful and famous monuments of Milan with the purpose of discovering the history of the city: Duomo, Galleria Vittorio Emanuele II, Teatro La Scala, Brera Art Design District.

The Organizing Secretariat reserves the right to modify the visits in case of bad weather.

Sunday April 22nd, 10.30 - 12.30

Visit to the Art Exhibition of Carlo Ceresa

Meeting point: Seminario Vescovile Beato "Giovanni XXIII" at 10.00


Over 100 works are divided into 9 sections: these are the numbers of an exhibit that will tell the story of a protagonist of the painting of the seventeenth century Lombardy. The exhibition begins in the exhibition of the Museum Bernareggi Adriano (The Youth of Carlo Ceresa and placement on the printout) and then continues in the halls of the nearby Accademia Carrara/GAMEC. Here the visitor will find, in a charming display, a bird's-eye survey of Baroque painting in Bergamo, in the time of Ceresa. A broad canvas on the main presences in Milan, Veneto, Liguria, Emilia Romagna and Tuscany, to which the painter of Bergamo opposes a strict and realistic language. The visit continues investigating his astounding debut as a portraitist in the years shortly after the memorable infection by Manzoni. On the front of the portrait painter is affirmed as of the local landmark, capturing the major personalities of the moment. The painting of sacred subjects will be particularly investigated since the turn of the forties, sanctioned by the reflection on the models of Daniel Crespi, the final season. The course concludes with a discussion on cultural heritage, left over, one of the great portrait painters of the eighteenth-century Europe: Between 'Galgario.



CITY OF BERGAMO

The city of Bergamo is located in Northern Italy, 50 kilometers from Milan, in the borderland between the great plain of the Po Valley and the Alps.

Bergamo was founded on a hill by an ancient settlement in the prehistorical age, which gave it the configuration that still characterizes the oldest part of the town, enclosed within walls up on the hill, while the modern town has grown on the plain. Celts, Goths, Romans, Longbards resided on the hill, but little can now be seen of them; some of the most important monuments date back to the Middle Ages. The town reached its greatest splendor during the Renaissance when it became part of the Milan Signoria and then of the Venetian Republic. The four centuries under the Venetians were the most significant with respect to their cultural and historical impact on the city.



Città Alta, the old town situated on the hill and surrounded by sixteenth-century walls, has maintained the charm of its past over the centuries, with the magic and quiet atmosphere of its belfries, towers and squares. Città Bassa, the modern town, has all the conveniences of a modern urban center. Thus, Bergamo is the town where old and new come together in a harmonious expression of life.



MAP OF BERGAMO



Meeting venue

- 1** Seminario Vescovile
Beato "Giovanni XXIII"
VIA MAZZINI

Hotels

- 2** Agnello d'Oro
- 3** Albergo Sole
- 4** ARLI
- 5** Berg-Hotel
- 6** Best Western
Hotel Cappello d'Oro
- 7** Excelsior San Marco
- 8** Gombit Hotel
- 9** Grand Hotel del Parco
- 10** Il Gourmet
- 11** La Valletta Resort
- 12** Mercure Bergamo
Palazzo Dolci
- 13** NH Bergamo Centro
- 14** NH Orio
- 15** Petronilla
- 16** Starhotel Cristallo Palace
- 17** Una Hotel



SATELLITE SYMPOSIA & LUNCH SESSION

Friday April 20th, 2012

LEO Pharma Satellite Symposium (Auditorium)

9.30 - 12.30

not CME accredited



CANCER AND THROMBOSIS: THE QUEST FOR OPTIMAL CARE

Chairs: Agnes YY Lee (Canada) and Peter Verhamme (Belgium)

Welcome and Introduction Chairs

VTE in cancer – the oncologist's view Hanno Riess (Germany)

Debate: Do low molecular weight heparins have anti-cancer effects? Peter Verhamme (Belgium)

- **YES** Ismail Elalamy (France)

- **NO** Pieter Kamphuisen (The Netherlands)

Questions from the audience

Coffee break

Unanswered clinical questions Marc Carrier (Canada)

Quality of life in cancer patients with VTE: treatment-related issues Simon Noble (UK)

Panel discussion Chair: Agnes YY Lee (Canada)

Conclusions Chairs

Friday April 20th, 2012

ROVI Satellite Symposium (Room "Aula Magna Orlandi")

11.30 - 13.00

not CME accredited



CANCER AND ANTICOAGULATION: LATEST UPDATES WITH LMWH

Welcome and Introduction Chair: Vicente Vicente (Spain)

Effect of LMWHs and ULMWH on the angiogenic properties of microvascular endothelium cells induced by tumour cells Anna Falanga (Italy)

Optimal duration of thromboprophylaxis using LMWH in patients undergoing major cancer surgery and latest recommendations Giancarlo Agnelli (Italy)

Anticoagulation and survival improvement in patients with small-cell lung cancer

Ramón Lecumberri (Spain)

Conclusions Vicente Vicente (Spain)

Saturday April 21st, 2012

BOEHRINGER INGELHEIM Italia Lunch Session (Room B)

13.15 - 14.15

not CME accredited



DABIGATRAN ETEXILATE IN THE STROKE PREVENTION IN ATRIAL FIBRILLATION

Chair: Giancarlo Agnelli (Italy)

Speaker: Walter Ageno (Italy)

This lunch session will be held in Italian

SPONSORS

Platinum



Gold



Silver



Bayer HealthCare
Bayer Schering Pharma



Boehringer
Ingelheim

Bronze



www.ictthic.com

SCIENTIFIC SECRETARIAT

Anna Falanga, Marina Marchetti, Alfonso Vignoli

Division of Immunohematology and Transfusion Medicine

& Hemostasis and Thrombosis Center

A.O. Ospedali Riuniti di Bergamo

Largo Barozzi, 1 - 24128 Bergamo, Italy

e-mail: scientificsecretariat@ictthic.com

ORGANIZING SECRETARIAT

C.E.C. Srl - Servizi Congressuali ed Eventi Culturali

Via G. Verdi 18 - 24121 Bergamo - Italy

Phone +39.035.249899 - Fax +39.035.237852

E-mail: info@ictthic.com

